Literature DB >> 26265365

Breast-Conserving Surgery in Bilateral Breast Cancer.

Julie A O'Brien1, Alice Ho, G Paul Wright, Michelle Stempel, Sujata Patil, Kate Krause, Monica Morrow, Mary L Gemignani.   

Abstract

BACKGROUND: Bilateral breast cancer (BBC) may present as synchronous (SBC) or metachronous breast cancer (MBC). Optimal surgical management of BBC patients is not well-defined. In this study, we report on histopathology, treatment, and outcomes in BBC patients.
METHODS: Upon Institutional Review Board approval, we identified BBC patients diagnosed and treated for invasive breast cancer between 1999 and 2007. Retrospective chart review for demographics, histopathology, treatment, and outcomes was performed, and factors associated with BCS choice were collected. Contraindication to BCS was defined as any of the following one-breast findings: multicentric disease, tumor considered too large for BCS, and a patient without a nominal breast size for acceptable cosmetic results. McNemar's test for matched pairs (binary variables) or the paired t test (continuous variables) were used to examine if a pathologic characteristic differed within a cancer pair. Kaplan-Meier methods estimated overall survival (OS).
RESULTS: A total of 203 BBC patients (119 SBC, 84 MBC) comprised our study group. Histopathologic characteristics of the first and second cancers diagnosed in both the SBC and MBC patients were very similar in histologic type and molecular profiles. Overall, 57% of MBC patients underwent breast-conserving surgery (BCS) at initial diagnosis versus 34% of patients with SBC. BCS contraindications were similar in both groups: 16 (34%) MBC patients and 28 (36%) SBC patients. Kaplan-Meier OS estimates at 5 and 10 years were 86 and 78% for MBC, and 87 and 77% for SBC patients, respectively.
CONCLUSIONS: OS was excellent for both the MBC and SBC groups. Contraindications to BCS did not differ between groups. However, patients with SBC were less likely to undergo BCS compared with patients with MBC at the time of initial diagnosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26265365      PMCID: PMC4636081          DOI: 10.1245/s10434-015-4746-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

1.  Diagnosis of metachronous contralateral breast cancer.

Authors:  R S Samant; I A Olivotto; J S Jackson; D Mates
Journal:  Breast J       Date:  2001 Nov-Dec       Impact factor: 2.431

2.  Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.

Authors:  Maria E C Sandberg; Mikael Hartman; Daniel Klevebring; Sandra Eloranta; Alexander Ploner; Per Hall; Kamila Czene
Journal:  Breast Cancer Res Treat       Date:  2012-05-24       Impact factor: 4.872

3.  Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease.

Authors:  D E Heron; L T Komarnicky; T Hyslop; G F Schwartz; C M Mansfield
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

4.  A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes.

Authors:  Alan M Nichol; Rinat Yerushalmi; Scott Tyldesley; Mary Lesperance; Chris D Bajdik; Caroline Speers; Karen A Gelmon; Ivo A Olivotto
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

5.  Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience.

Authors:  Robert Díaz; Blanca Munárriz; Ana Santaballa; Laura Palomar; Joaquín Montalar
Journal:  Med Oncol       Date:  2010-12-31       Impact factor: 3.064

6.  Prognosis of early-stage synchronous bilateral invasive breast cancer.

Authors:  S M Schmid; C Pfefferkorn; M E Myrick; C T Viehl; E Obermann; A Schötzau; U Güth
Journal:  Eur J Surg Oncol       Date:  2011-05-31       Impact factor: 4.424

7.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Authors:  Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2011-03-11       Impact factor: 13.506

8.  Synchronous, bilateral breast cancer: prognostic value and incidence.

Authors:  J J Jobsen; J van der Palen; F Ong; J H Meerwaldt
Journal:  Breast       Date:  2003-04       Impact factor: 4.380

9.  The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours.

Authors:  A R Carmichael; S Bendall; L Lockerbie; R Prescott; T Bates
Journal:  Eur J Surg Oncol       Date:  2002-06       Impact factor: 4.424

10.  Histo-biological comparative analysis of bilateral breast cancer.

Authors:  Bilal Baker; Basem Morcos; Faiez Daoud; Maher Sughayer; Maher Sughayyer; Hisham Shabani; Habeeb Salameh; Mahmoud Almasri
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

View more
  9 in total

1.  Effect of breast-conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer.

Authors:  Chao Qian; Yan Liang; Min Yang; Sheng-Nan Bao; Jian-Ling Bai; Yong-Mei Yin; Hao Yu
Journal:  Gland Surg       Date:  2021-10

2.  Clinical characteristics and the associated risk factors of the development of bilateral breast cancers: A case-control study.

Authors:  Sumadi Lukman Anwar; Dayat Prabowo; Widya Surya Avanti; Ery Kus Dwianingsih; Wirsma Arif Harahap; Teguh Aryandono
Journal:  Ann Med Surg (Lond)       Date:  2020-11-04

3.  Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer.

Authors:  Shuning Ding; Xi Sun; Shuangshuang Lu; Zheng Wang; Xiaosong Chen; Kunwei Shen
Journal:  Breast       Date:  2021-03-20       Impact factor: 4.380

4.  Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography.

Authors:  Joost R C Lameijer; Angela Mp Coolen; Adri C Voogd; Luc J Strobbe; Marieke W J Louwman; Dick Venderink; Vivian C Tjan-Heijnen; Lucien E M Duijm
Journal:  Eur Radiol       Date:  2018-04-17       Impact factor: 5.315

5.  The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018).

Authors:  Bo Pan; Ying Xu; Yi-Dong Zhou; Ru Yao; Huan-Wen Wu; Qing-Li Zhu; Chang-Jun Wang; Feng Mao; Yan Lin; Song-Jie Shen; Qiang Sun
Journal:  Cancer Med       Date:  2019-04-30       Impact factor: 4.452

6.  Bilateral oncoplastic breast-conserving surgery with volume replacement technique using the omental flap: a case report.

Authors:  Hisamitsu Zaha; Norie Abe; Hirofumi Matsumoto; Ayako Koki; Mikiko Unesoko
Journal:  Surg Case Rep       Date:  2022-05-09

7.  Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series.

Authors:  Alexandre Huber; Stéphanie J Seidler; Daniela E Huber
Journal:  Eur J Breast Health       Date:  2020-04-01

8.  The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer.

Authors:  G W Irwin; F Bannon; C E Coles; E Copson; R I Cutress; R V Dave; M Grayson; C Holcombe; S Irshad; C O'Brien; R L O'Connell; C Palmieri; A M Shaaban; N Sharma; J Singh; I Whitehead; S Potter; S A McIntosh
Journal:  Int J Surg Protoc       Date:  2019-11-11

9.  Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016).

Authors:  Hanfang Jiang; Ruyan Zhang; Xiaoran Liu; Ran Ran; Jiayang Zhang; Yaxin Liu; Xinyu Gui; Yifei Chen; Kun Li; Bin Shao; Ying Yan; Xu Liang; Guohong Song; Lijun Di; Huiping Li
Journal:  Cancer Med       Date:  2021-08-04       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.